Encube Ethicals files its draft papers with India’s markets regulator, SEBI, to raise about Rs 3,000 crore through an initial public offering (IPO), according to multiple reports. The company is engaged in end-to-end development and manufacturing services for pharmaceutical clients and works with more than 160 pharma firms across 50 countries. In its financial disclosures for FY26, Encube Ethicals reports revenue from operations of Rs 1,848.7 crore and net profit of Rs 436.7 crore. The sources indicate that the filing marks the next step in the company’s plan to access public markets, subject to regulatory review. The reports do not provide further details on the IPO structure, such as the mix of fresh issue versus offer for sale, or the expected timeline for approvals. Overall, the coverage focuses on the SEBI filing, the target fundraising amount of Rs 3,000 crore, the company’s global client base, and the stated FY26 financial performance.